Victory Capital Management Inc. Raises Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Victory Capital Management Inc. boosted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 174.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 19,899 shares of the company’s stock after acquiring an additional 12,643 shares during the period. Victory Capital Management Inc.’s holdings in Kymera Therapeutics were worth $801,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of KYMR. Massachusetts Financial Services Co. MA boosted its holdings in shares of Kymera Therapeutics by 11.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company’s stock valued at $21,458,000 after purchasing an additional 47,507 shares during the last quarter. Eventide Asset Management LLC increased its position in shares of Kymera Therapeutics by 9.9% in the 3rd quarter. Eventide Asset Management LLC now owns 507,902 shares of the company’s stock worth $24,039,000 after purchasing an additional 45,803 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Kymera Therapeutics in the 3rd quarter worth about $650,000. JPMorgan Chase & Co. increased its position in shares of Kymera Therapeutics by 212.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock worth $6,649,000 after purchasing an additional 95,547 shares during the last quarter. Finally, Natixis Advisors LLC bought a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at about $681,000.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on KYMR. BTIG Research initiated coverage on shares of Kymera Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective for the company. Citigroup began coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 price target for the company. Leerink Partners reissued an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. BMO Capital Markets started coverage on shares of Kymera Therapeutics in a research note on Friday, December 6th. They set a “market perform” rating and a $55.00 target price for the company. Finally, Stephens restated an “overweight” rating and set a $60.00 price target on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Kymera Therapeutics Stock Down 1.9 %

KYMR stock opened at $33.21 on Friday. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -14.19 and a beta of 2.22. Kymera Therapeutics, Inc. has a 12 month low of $29.07 and a 12 month high of $53.27. The firm has a 50 day moving average of $36.90 and a two-hundred day moving average of $42.44.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The firm had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. On average, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares of the company’s stock, valued at $6,147,428.70. This represents a 3.37 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Ellen Chiniara sold 2,241 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now owns 80,085 shares of the company’s stock, valued at approximately $2,438,588.25. This represents a 2.72 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 13,788 shares of company stock valued at $455,202. Company insiders own 15.82% of the company’s stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.